National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lenvatinib (Kisplyx®). HTA ID: 22057

Lenvatinib (Kisplyx®) is indicated for the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/08/2022
Rapid review completed 22/09/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib in combination with pembrolizumab for the first-line treatment of patients with advanced RCC compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.